Elsevier

Neuroscience Letters

Volume 443, Issue 3, 10 October 2008, Pages 236-240
Neuroscience Letters

Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats

https://doi.org/10.1016/j.neulet.2008.07.074Get rights and content

Abstract

Neurochemical studies suggest that baclofen, an agonist at GABAB receptors, may be useful for treatment of nicotine dependence. However, its ability to selectively reduce nicotine's abuse-related behavioral effects remains in question. We assessed effects of baclofen doses ranging from 0.1 to 3 mg/kg on nicotine-induced conditioned place preferences (CPPs), nicotine discrimination, locomotor activity and food-reinforced behavior in male Sprague–Dawley rats. The high dose of baclofen (3 mg/kg) totally eliminated food-reinforced responding and significantly decreased locomotor activity. Lower doses of baclofen did not have nicotine-like discriminative effects in rats trained to discriminate 0.4 mg/kg nicotine from saline under a fixed-ratio 10 schedule of food delivery. Lower doses of baclofen also did not reduce discriminative stimulus effects of the training dose of nicotine and did not significantly shift the dose–response curve for nicotine discrimination. Rats treated with the high 3 mg/kg dose of baclofen did not express nicotine-induced CPP. These experiments, along with previous reports that baclofen can reduce intravenous nicotine self-administration behavior, confirm the potential utility of baclofen as a tool for smoking cessation.

Section snippets

Acknowledgements

This study was supported by NIDA-IRP, DHHS. BLF has received the support of the CIHR-TUSP training program.

References (47)

  • W.K. Schiffer et al.

    Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study

    Life Sci.

    (2000)
  • M. Shoaib et al.

    The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion

    Neuropharmacology

    (2002)
  • C.R. Ashby et al.

    Systemic administration of 1R,4S-4-amino-cyclopent-2-ene-carboxylic acid, a reversible inhibitor of GABA transaminase, blocks expression of conditioned place preference to cocaine and nicotine in rats

    Synapse

    (2002)
  • K. Brebner et al.

    A potential role for GABA(B) agonists in the treatment of psychostimulant addiction

    Alcohol Alcohol.

    (2002)
  • K. Brebner et al.

    Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules

    Psychopharmacology (Berl.)

    (2000)
  • U.C. Campbell et al.

    Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats

    Psychopharmacology (Berl.)

    (1999)
  • C. Cohen et al.

    SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

    Behav. Pharmacol.

    (2002)
  • M.S. Cousins et al.

    Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking

    Nicotine Tob. Res.

    (2001)
  • R.I. Desai et al.

    Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats

    Psychopharmacology (Berl.)

    (2003)
  • S.L. Dewey et al.

    A pharmacologic strategy for the treatment of nicotine addiction

    Synapse

    (1999)
  • P. Di Ciano et al.

    The GABA(B) receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats

    Neuropsychopharmacology

    (2003)
  • T. Eke et al.

    Severe persistent visual field constriction associated with vigabatrin

    BMJ

    (1997)
  • P. Fadda et al.

    Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat

    Synapse

    (2003)
  • Cited by (0)

    View full text